Abstract 4146824: Performance of Clinician-Assigned SCAI Shock Staging in the AHA Cardiogenic Shock Registry

Background: SCAI staging of cardiogenic shock (CS) severity facilitates communication about the presentation and trajectory of CS. Most prior validations of SCAI staging have used registry-specific algorithmic adaptations of the staging criteria. Few studies have evaluated clinician-assigned SCAI staging based on holistic assessment of all clinical data. Aim: To assess the ability of initial and serial clinician-assigned SCAI staging to stratify risk of in-hospital mortality in a large, broadly representative CS population from the AHA CS Registry. Methods: Consecutive CS admissions enrolled in the Registry (64 sites, 2022-2024) were included. Clinician-assigned SCAI stage was captured at CS onset (first 6h) and serially (6-12h after CS onset). Cases with available SCAI stage at both timepoints were classified as having improved, unchanged, or worsened SCAI stage. Associations of in-hospital mortality with initial and early change in SCAI stage were assessed using logistic regression; for the latter, models were adjusted for initial SCAI stage. Key subgroups defined by CS etiology (AMI-CS vs. HF-CS) and preceding cardiac arrest (CA) were examined. Results: Among 4,311 CS admissions, 3,110 (72%) had initial SCAI stage assessments (median age 66y, 33% women, 30% AMI-CS, 50% HF-CS, 21% preceding CA) and 2,867 (67%) had serial assessments. Most CS was initially staged as SCAI C (B: 12%; C: 59%; D: 19%; E: 10%), with a higher proportion of SCAI D/E in those with AMI-CS (34%) or preceding CA (60%). There was a stepwise gradient of mortality across SCAI stages (p<0.001; Fig-A ), consistent when stratifying by CS etiology and preceding CA (p<0.001 for each; Fig-B/C ). In the 12h after CS onset, most SCAI staging was unchanged (73%; worsening: 15%; improving: 12%); however, SCAI staging was more dynamic in those with preceding CA. Early worsening or improvement in SCAI stage was associated with higher (aOR 3.7, 95% CI 2.9-4.6) and lower (aOR 0.4, 95% CI 0.3-0.5) odds of mortality, respectively ( Fig-D ). Conclusion: In this initial analysis from the AHA CS Registry, clinician-assigned SCAI staging effectively stratified in-hospital mortality risk, and early changes in SCAI stage further refined prognostication in CS.